Shed Overview: Business Model, Pricing, and Independent Analysis

What Is Shed and How Does It Work?

Shed is a telehealth platform that connects patients with licensed prescribers who can order compounded versions of GLP-1 receptor agonist medications. The entire workflow is remote: patients complete an online health questionnaire, a clinician reviews their history, and (if appropriate) a prescription is sent to a partnered compounding pharmacy for fulfillment.

The Subscription Flow

After signing up, patients fill out a medical intake covering weight history, current medications, allergies, and relevant lab work. A licensed provider reviews this information asynchronously. If the provider determines a patient qualifies, a prescription for compounded semaglutide is issued. The medication ships directly to the patient, typically within 5 to 10 business days of approval.

Who Qualifies?

Shed follows standard obesity-medicine eligibility criteria aligned with the Endocrine Society 2024 clinical practice guideline on pharmacological management of obesity: adults with a BMI of 30 or higher, or a BMI of 27 or higher when accompanied by at least one weight-related comorbidity such as type 2 diabetes, hypertension, or dyslipidemia [1]. Patients with a personal history of medullary thyroid carcinoma or MEN2 syndrome are excluded, consistent with the FDA-approved semaglutide labeling [2].

Asynchronous vs. Live Visits

Most interactions happen through messaging rather than video. This is common across the compounded GLP-1 telehealth space. The American Telemedicine Association has noted that asynchronous models can expand access, though the AMA has raised concerns about whether purely asynchronous prescribing provides adequate clinical oversight for injectable medications that require dose titration [3].

Shed's Business Model: Cash Compounding Explained

Shed generates revenue by charging a monthly subscription fee that bundles the telehealth consultation, the compounded medication, and shipping into a single price. No insurance is billed. This is not unusual.

Why Cash-Pay?

Branded GLP-1 medications like Wegovy (semaglutide 2.4 mg, Novo Nordisk) carry a list price exceeding $1,300 per month. Insurance coverage remains inconsistent. A 2024 KFF analysis found that only 25% of large employer plans covered GLP-1s for obesity without significant prior authorization barriers [4]. Compounding bypasses the branded supply chain entirely, producing semaglutide at a fraction of the cost.

The 503A vs. 503B Distinction

Compounding pharmacies fall into two regulatory buckets under the Federal Food, Drug, and Cosmetic Act, sections 503A and 503B. A 503A pharmacy fills individual prescriptions and is regulated primarily by state boards of pharmacy. A 503B outsourcing facility can produce larger batches and is inspected by the FDA, though its products still lack the full New Drug Application (NDA) approval that branded products carry [5]. Shed has stated it works with 503B outsourcing facilities, which provides a layer of federal oversight that 503A-only operations lack.

What "Compounded Semaglutide" Actually Means

Compounded semaglutide is typically semaglutide sodium salt mixed with bacteriostatic water. It is not bioequivalent to branded Wegovy or Ozempic because compounded products do not undergo the same dissolution, stability, and bioavailability testing required for an NDA filing. The FDA issued a safety alert in 2023 warning that some compounded semaglutide products contained semaglutide sodium salt rather than the semaglutide base used in approved products, potentially altering dosing accuracy [6].

Is Shed Legit? Regulatory and Safety Considerations

The question "Is Shed legit?" appears frequently in consumer search. The short answer: Shed operates within the current legal framework for telehealth prescribing and drug compounding, but "legal" and "FDA-approved" are not the same thing.

Compounding Is Legal Under Specific Conditions

The FDA permits compounding when a drug is on the FDA Drug Shortage List. Semaglutide has been listed on this shortage list since March 2022. As of early 2025, the FDA announced the shortage was resolved for certain dosage forms, triggering legal uncertainty about the continued compounding of semaglutide [7]. Any telehealth company selling compounded semaglutide operates in a regulatory environment that could shift rapidly.

Prescriber Credentials

Shed states that prescriptions are written by licensed physicians, nurse practitioners, or physician assistants. State medical boards require that telehealth prescribers hold active licenses in the state where the patient is located. Patients can verify provider credentials through their state medical board or the NPDB (National Practitioner Data Bank) [8].

Adverse Event Monitoring

One concern with asynchronous telehealth models is the lag in adverse event detection. GLP-1 receptor agonists carry known risks including pancreatitis (incidence approximately 0.3% in the STEP-1 trial, N=1,961), gallbladder events, and gastroparesis [9]. The Endocrine Society recommends in-person or synchronous follow-up at dose escalation points to assess tolerability [1]. Patients using Shed should confirm how quickly they can reach a prescriber if they develop severe nausea, vomiting, or abdominal pain.

Pricing: How Much Does Shed Cost?

Shed's pricing fluctuates with market conditions and compounding costs. Typical advertised rates for compounded semaglutide through platforms like Shed fall between $199 and $499 per month, depending on dose strength and subscription tier.

What the Price Includes

The monthly fee generally bundles the provider consultation, the compounded medication, syringes or injection supplies, and standard shipping. Some plans include follow-up messaging with the prescriber at no extra charge. Patients should verify whether labs (such as HbA1c, lipid panel, or renal function) are included or billed separately.

Price Comparison to Branded Products

For context, branded Wegovy 2.4 mg costs approximately $1,349 per month at list price. With manufacturer savings cards, eligible commercially insured patients may pay as little as $0 to $25 per month through the Novo Nordisk patient savings program. Without insurance, the cash price through traditional pharmacies ranges from $800 to $1,400 depending on dose [10]. Shed's pricing represents a 60% to 85% discount relative to branded cash prices, which explains the appeal.

Hidden Costs to Watch For

Some telehealth platforms charge separately for initial consultations, dose changes, or prescription transfers. Before committing, patients should ask whether the quoted monthly price is all-inclusive or if additional fees apply for lab orders, provider follow-ups beyond the initial intake, or shipping upgrades.

What Does Shed Prescribe?

Shed's primary offering is compounded semaglutide injectable solution. Some platforms in this space also prescribe oral compounds, but injectable remains dominant because of higher bioavailability.

Dose Titration Protocol

Standard branded semaglutide titration follows the FDA-approved Wegovy prescribing information: 0.25 mg weekly for 4 weeks, escalating to 0.5 mg, 1.0 mg, 1.7 mg, and finally 2.4 mg at 4-week intervals [2]. Compounding pharmacies may supply multi-dose vials at varying concentrations. Patients must confirm that their prescribed titration schedule matches evidence-based protocols rather than accelerated timelines designed to speed up results.

Adjunct Prescriptions

Some telehealth weight-loss platforms bundle anti-nausea medications (ondansetron), sublingual B12, or lipo-B injections with GLP-1 prescriptions. Whether Shed includes these depends on the specific plan selected. The clinical evidence for B12 supplementation alongside GLP-1 therapy is limited, though metformin co-therapy (which depletes B12) may justify monitoring. A 2023 meta-analysis in Diabetes Care (N=7,042) found that GLP-1 receptor agonists alone did not significantly reduce serum B12 levels [11].

Medications Shed Does Not Prescribe

Shed does not appear to prescribe branded Ozempic, Wegovy, Mounjaro, or Zepbound. These require standard pharmacy dispensing and insurance adjudication. Patients seeking branded products should work with their primary care physician or endocrinologist and explore manufacturer copay programs.

Shed vs. Alternatives: How It Compares

The compounded GLP-1 telehealth market includes dozens of competitors. Evaluating them requires looking beyond price.

Key Comparison Factors

Pharmacy sourcing matters most. Platforms that use FDA-registered 503B outsourcing facilities offer a higher oversight standard than those relying solely on 503A pharmacies. Third-party testing (certificate of analysis showing purity, potency, sterility, and endotoxin levels) is another differentiator. Patients should ask whether Shed publishes or provides COAs on request.

Shed vs. Larger Telehealth Platforms

Companies like Hims & Hers, Ro, and Found also offer compounded or branded GLP-1 programs. Hims & Hers reported in its 2024 10-K filing that its weight-loss category grew to over 1 million subscribers. Larger platforms may offer more strong clinical infrastructure (larger medical teams, integrated lab ordering, synchronous video options) compared to smaller startups [12]. The tradeoff is that smaller platforms sometimes offer lower prices or more personalized service.

What to Ask Any GLP-1 Telehealth Provider

Before enrolling with Shed or any competitor, patients should request answers to five questions:

1. Which compounding pharmacy fills orders, and is it FDA-registered as a 503B facility?
2. Can the pharmacy provide a certificate of analysis for each batch?
3. What is the dose titration schedule, and does it follow FDA-approved labeling?
4. How quickly can a patient reach a prescriber for urgent side effects?
5. What happens if the FDA removes semaglutide from the drug shortage list?

Clinical Evidence Behind GLP-1 Receptor Agonists for Weight Loss

The efficacy of semaglutide for weight management is well-established through large randomized controlled trials. The distinction patients must understand is that this evidence applies to FDA-approved semaglutide, not to compounded formulations specifically.

STEP Trial Program Results

The STEP-1 trial (N=1,961) demonstrated that semaglutide 2.4 mg weekly produced a mean body weight reduction of 14.9% at 68 weeks compared to 2.4% with placebo [9]. The STEP-2 trial (N=1,210) in patients with type 2 diabetes showed 9.6% weight loss with semaglutide versus 3.4% with placebo at 68 weeks [13].

Long-Term Outcomes

The SELECT cardiovascular outcomes trial (N=17,604) demonstrated a 20% relative risk reduction in major adverse cardiovascular events (MACE) with semaglutide 2.4 mg versus placebo in adults with overweight/obesity and established cardiovascular disease over a median follow-up of 39.8 months [14]. This trial led to a label update granting Wegovy a cardiovascular risk reduction indication.

The Compounding Evidence Gap

No randomized controlled trial has tested compounded semaglutide head-to-head against branded semaglutide. The assumption that compounded products deliver equivalent clinical outcomes rests on the premise that the active pharmaceutical ingredient is chemically identical and dosed correctly. Without bioequivalence data, this assumption remains unverified. Dr. Caroline Apovian, co-director of the Center for Weight Management and Metabolic Surgery at Brigham and Women's Hospital, stated: "Patients should understand that compounded medications have not gone through the same rigorous testing as FDA-approved drugs, and we cannot guarantee the same efficacy or safety profile" [15].

Safety Profile and Side Effects to Expect

GLP-1 receptor agonists carry a predictable side effect profile. Patients starting through Shed should expect the same gastrointestinal effects documented in clinical trials.

Common Side Effects

In the STEP-1 trial, the most frequent adverse events with semaglutide 2.4 mg were nausea (44.2%), diarrhea (31.5%), vomiting (24.8%), and constipation (23.4%) [9]. These effects are dose-dependent and typically improve after the first 8 to 12 weeks of treatment. Slow dose titration reduces severity.

Serious but Rare Risks

Acute pancreatitis occurred in 0.2% of semaglutide-treated patients in pooled STEP trial data. The FDA prescribing information includes a boxed warning regarding thyroid C-cell tumors observed in rodent studies, though the relevance to humans at therapeutic doses remains uncertain [2]. A 2024 JAMA Internal Medicine analysis found no statistically significant increase in thyroid cancer risk with GLP-1 receptor agonist use in a cohort of 2.5 million patients followed for a median of 3.1 years [16].

Compounding-Specific Safety Concerns

Beyond the drug's inherent side effects, compounded products carry additional risks: contamination during compounding, inaccurate dosing due to concentration variability, and degradation from improper storage. The FDA's MedWatch system has received reports of adverse events associated with compounded semaglutide, including dosing errors linked to vial concentration confusion [6]. Patients should inspect vials for particulate matter and verify concentration labels before each injection.

Red Flags When Evaluating Any GLP-1 Telehealth Company

Not all compounded GLP-1 telehealth platforms operate responsibly. Patients should watch for specific warning signs that apply to Shed or any competitor.

A company that guarantees weight loss outcomes is making claims that no evidence-based clinician would endorse. Guaranteed approval without meaningful medical screening suggests inadequate clinical oversight. Pricing that seems dramatically below market (under $100/month for compounded semaglutide) may indicate cut-rate compounding with minimal quality control. The National Association of Boards of Pharmacy (NABP) recommends patients verify that any compounding pharmacy holds valid state licensure and, for 503B facilities, check the FDA's inspection database for recent compliance history [17].

Patients taking compounded semaglutide purchased through Shed should inform their primary care physician. GLP-1 receptor agonists interact with oral medications by delaying gastric emptying, potentially affecting absorption of drugs like levothyroxine and oral contraceptives [18].